ライフサイエンスコーパス: tocilizumab

1 p=0.59 for tocilizumab plus methotrexate vs tocilizumab).

2 response, using the IL-6 receptor antagonist tocilizumab.

3 ance metrics after treatment initiation with tocilizumab.

4 nt after IL-6 receptor-directed therapy with tocilizumab.

5 tudies are needed to confirm the efficacy of tocilizumab.

6 nd alemtuzumab (anti-CD52), before receiving tocilizumab.

7 ent-year), occurred in patients who received tocilizumab.

8 eria for nonresponse were offered open-label tocilizumab.

9 n-6 (anti-IL-6) receptor monoclonal antibody tocilizumab.

10 gents, followed by abatacept, rituximab, and tocilizumab.

11 interleukin-6 receptor monoclonal antibody, tocilizumab.

12 those receiving monotherapy with 2 mg/kg of tocilizumab.

13 ne the durability of remission and safety of tocilizumab.

14 ted with the interleukin-6 receptor antibody tocilizumab.

15 h the difference eliminated upon addition of tocilizumab.

16 onist anakinra and the IL-6 receptor blocker tocilizumab.

17 rologic toxicities and CRS not responsive to tocilizumab.

18 tumor necrosis factor-alpha antagonists and tocilizumab.

19 SD) of 30.9 (15.9) months after switching to tocilizumab.

20 l as reveals a novel mechanism of action for tocilizumab.

21 ith the anti-interleukin-6 receptor antibody tocilizumab.

22 on of tumor cells in vitro as effectively as tocilizumab.

23 ndomly assigned (1:1) to weekly subcutaneous tocilizumab 162 mg or placebo.

24 r necrosis factor-alpha antagonists [80%] or tocilizumab [20%]) and fulfilling American College of Rh

25 luding B-cell depletion, and who switched to tocilizumab (6-8 mg/kg of body weight per dose).

26 Questionnaire showed greater decreases with tocilizumab 8 mg/kg and 4 mg/kg (-144.1 and -128.4 units

27 ained on stable doses of DMARDs and received tocilizumab 8 mg/kg or placebo (control group) every 4 w

28 -modified Sharp score was 0.29 and 0.34 with tocilizumab 8 mg/kg plus MTX and 4 mg/kg plus MTX, respe

29 Patients received tocilizumab (8 mg/kg or 4 mg/kg) or placebo every 4 week

30 herapeutic regimen with monthly infusions of tocilizumab (8 mg/kg) may increase efficacy.

31 Like tofacitinib, tocilizumab, a biologic targeting the IL-6 pathway, has

32 as subsequent IL-6 receptor blockade through tocilizumab, a complete and stable remission of symptoms

33 Blockade of IL6 signaling with tocilizumab, a drug approved by the Food and Drug Admini

34 ntation of a B-cell-anergizing therapy using tocilizumab, a humanized monoclonal antibody against the

35 Five attacks were associated with delayed tocilizumab administration (>/=40 days), and 6 attacks w

36 Adalimumab, etanercept, infliximab and tocilizumab all showed statistically significant improve

37 ies demonstrate that immunosuppression using tocilizumab, an anti-IL-6 receptor antibody, with or wit

38 The efficacy and safety of tocilizumab, an interleukin 6 receptor-alpha inhibitor,

39 We enrolled 87 patients: 43 assigned to tocilizumab and 44 assigned to placebo.

40 occurred in 6.7% and 4.3% of patients in the tocilizumab and control groups, respectively, and seriou

41 penia occurred in 3.7% of patients receiving tocilizumab and none of the patients in the control grou

42 Tocilizumab and rituximab have been shown to lead to imp

43 Tocilizumab and rituximab may also be of benefit in refr

44 -methotrexate) was tapered and stopped, then tocilizumab (and placebo-tocilizumab) was also tapered a

45 ngly inhibited by an IL-6 receptor antibody (tocilizumab) and less well by TNF-alpha and IL-1beta ant

46 ptor was blocked with a monoclonal antibody (tocilizumab), and signal transducer and activator of tra

47 Among these is tocilizumab (anti-IL-6 receptor [IL-6R]) which holds pro

48 available randomized controlled trial data, tocilizumab appears effective in TNFi failure group, irr

49 s methotrexate arm vs 19 [18%] of 103 in the tocilizumab arm and 13 [12%] of 108 in the methotrexate

50 r tocilizumab plus placebo-methotrexate (the tocilizumab arm), or methotrexate plus placebo-tocilizum

51 ocilizumab plus methotrexate arm, 103 to the tocilizumab arm, and 108 to the methotrexate arm).

52 lus methotrexate arm, 40 (39%) of 103 in the tocilizumab arm, and 37 (34%) of 108 in the methotrexate

53 egimen, compared with 86 (84%) of 103 in the tocilizumab arm, and 48 (44%) of 108 in the methotrexate

54 lus methotrexate arm, 91 (88%) of 103 in the tocilizumab arm, and 83 (77%) of 108 in the methotrexate

55 Use of tocilizumab as additional treatment with prednisone show

56 of patients receiving 4 mg/kg and 8 mg/kg of tocilizumab as monotherapy, respectively, and by 63% and

57 eous forms of existing therapies (abatacept, tocilizumab), as well as newer-generation monoclonal ant

58 omized to 1 of 7 treatment arms, as follows: tocilizumab at doses of 2 mg/kg, 4 mg/kg, or 8 mg/kg eit

59 in a 2:1:1:1 ratio, to receive subcutaneous tocilizumab (at a dose of 162 mg) weekly or every other

60 to the anti-interleukin-6 receptor antibody tocilizumab (at a dose of 8 mg per kilogram of body weig

61 Tocilizumab combined with any of the DMARDs evaluated wa

62 rapy using the humanized monoclonal antibody tocilizumab directed against the interleukin 6 (IL-6) re

63 , and 6 attacks were associated with reduced tocilizumab dosage (6 vs 8 mg/kg).

64 kly, 14% of those in the group that received tocilizumab every other week, 22% of those in the placeb

65 umab weekly and in 53% of those treated with tocilizumab every other week, as compared with 14% of th

66 ed in one patient in the group that received tocilizumab every other week.

67 inhibitors (TNFi), rituximab, abatacept and tocilizumab, following TNFi failure with no comparative

68 pt and anakinra had failed, was administered tocilizumab for 6 months, and the therapeutic response w

69 gs merit attention in any clinical trials of tocilizumab for GVHD prevention or treatment and provide

70 ed with the IL-6 receptor (IL-6R) antagonist tocilizumab for the treatment of large-vessel vasculitid

71 Tocilizumab generally was well tolerated and no serious

72 ity were assigned to receive 1 of 3 doses of tocilizumab given intravenously every other week for 12

73 Serious infections were more common in the tocilizumab group (seven [16%] of 43 patients) than in t

74 dnan skin score at 24 weeks was -3.92 in the tocilizumab group and -1.22 in the placebo group (differ

75 res mean change at 48 weeks was -6.33 in the tocilizumab group and -2.77 in the placebo group (treatm

76 of normal, occurred in 4% of patients in the tocilizumab group and 1% of those in the control group,

77 study were infrequent (4% of patients in the tocilizumab group and 2% of those in the control group).

78 ry outcome was the rate of remission in each tocilizumab group as compared with the placebo group tha

79 ocorticoid-free remission at week 52 in each tocilizumab group as compared with the rate in the place

80 IL-8 increased, while CRP decreased, in the tocilizumab group compared with the placebo group.

81 Seventy-three percent of patients in the tocilizumab group had >or=1 adverse event (AE), compared

82 as met in significantly more patients in the tocilizumab group than in the placebo group (64 of 75 [8

83 However, the difference was greater in the tocilizumab group than in the placebo group and we found

84 exploratory analyses, fewer patients in the tocilizumab group than in the placebo group had a declin

85 42 (98%) of 43 patients in the tocilizumab group versus 40 (91%) of 44 in the placebo g

86 over the 52-week period was 1862 mg in each tocilizumab group, as compared with 3296 mg in the place

87 g 60 infections (2 serious), occurred in the tocilizumab group, as compared with 38, including 15 inf

88 At week 52, 80% of the patients who received tocilizumab had at least 70% improvement with no fever,

89 Tocilizumab has a well-characterized safety profile.

90 gnaling with the anti-IL-6 receptor antibody tocilizumab has provided some clinical benefit to patien

91 lizing Abs, such as the anti-IL6 receptor Ab tocilizumab, have demonstrated rapid and sustained impro

92 Treatment with tocilizumab in 13 subjects resulted in rapid defervescen

93 tudies are needed to confirm the efficacy of tocilizumab in autoimmune synaptic or presynaptic diseas

94 ind, placebo-controlled, multicenter TOWARD (Tocilizumab in Combination With Traditional DMARD Therap

95 neutropenia may limit the maximum dosage of tocilizumab in patients with SLE, the observed clinical

96 tumor necrosis factor-alpha antagonists and tocilizumab) in patients with Takayasu arteritis.

97 ging lesions were seen in 6 of 8 patients at tocilizumab initiation and in 1 of 8 patients at the las

98 Tocilizumab is a humanized mAb to IL6-receptor-alpha (IL

99 Tocilizumab is a recombinant humanized monoclonal antibo

100 Tocilizumab is the first-in-class drug developed to trea

101 After the switch to tocilizumab (median duration of therapy, 18 months), the

102 Tocilizumab might be effective in NMO, here in a patient

103 are elevated in TRAPS, we hypothesized that tocilizumab might be effective.

104 g plasma cells, suggest a specific effect of tocilizumab on autoantibody-producing cells.

105 f the interleukin-6 receptor alpha inhibitor tocilizumab on the rates of relapse during glucocorticoi

106 Incubation of HCC cell lines with tocilizumab or knockdown of signal transducer and activa

107 izophrenia to 3 monthly infusions of 8 mg/kg tocilizumab or placebo (normal saline).

108 nfliximab (anti-TNF-[Formula: see text]) and tocilizumab or siltuximab (anti-IL-6/IL-6R).

109 ent (ACR20) was significantly greater in the tocilizumab plus DMARD group than in the control group (

110 and hemoglobin levels showed superiority of tocilizumab plus DMARDs over DMARDs alone.

111 randomly assigned patients (1:1:1) to start tocilizumab plus methotrexate (the tocilizumab plus meth

112 91 (86%) of 106 patients in the tocilizumab plus methotrexate arm achieved sustained rem

113 lacebo to active treatments; patients in the tocilizumab plus methotrexate arm switched to standard o

114 ment groups (17 [16%] of 106 patients in the tocilizumab plus methotrexate arm vs 19 [18%] of 103 in

115 to start tocilizumab plus methotrexate (the tocilizumab plus methotrexate arm), or tocilizumab plus

116 7 eligible patients to treatment (106 to the tocilizumab plus methotrexate arm, 103 to the tocilizuma

117 occurring in 38 (36%) of 106 patients in the tocilizumab plus methotrexate arm, 40 (39%) of 103 in th

118 ntire study, 91 (86%) of 106 patients in the tocilizumab plus methotrexate arm, 91 (88%) of 103 in th

119 ssion (RR 1.13, 95% CI 1.00-1.29, p=0.06 for tocilizumab plus methotrexate vs methotrexate, 1.14, 1.0

120 elative risk [RR] 2.00, 95% CI 1.59-2.51 for tocilizumab plus methotrexate vs methotrexate, and 1.86,

121 tocilizumab vs methotrexate, and p=0.59 for tocilizumab plus methotrexate vs tocilizumab).

122 on therapy with either 4 mg/kg or 8 mg/kg of tocilizumab plus MTX (P < 0.05).

123 The findings of this study show that tocilizumab plus MTX results in greater inhibition of jo

124 and 74% of patients receiving those doses of tocilizumab plus MTX, respectively, compared with 41% of

125 eceiving combination therapy with 8 mg/kg of tocilizumab plus MTX.

126 (the tocilizumab plus methotrexate arm), or tocilizumab plus placebo-methotrexate (the tocilizumab a

127 body against interleukin-6 receptor (IL-6R), tocilizumab, prevented M2-differentiation.

128 Tocilizumab, received weekly or every other week, combin

129 Interleukin-6 receptor blockade with tocilizumab remains the mainstay pharmacologic therapy f

130 r novel therapies such as ACTH analogues and tocilizumab require additional investigation.

131 The efficacy and safety of tocilizumab should be investigated in a phase 3 trial be

132 systemic symptoms, while the IL-6 inhibitor tocilizumab shows great potential.

133 erent doses of intravenous (IV) infusions of tocilizumab (TCZ), an IL-6 inhibitor, in eyes with nonin

134 ing a novel drug (anti-IL-6 receptor (IL-6R),Tocilizumab [TCZ]) + intravenous Ig (IVIg) to assess saf

135 ssion were higher in those receiving 8 mg/kg tocilizumab than in those receiving placebo (P < 0.0001

136 cilizumab arm), or methotrexate plus placebo-tocilizumab (the methotrexate arm).

137 majority of patients who received 8 mg/kg of tocilizumab, the C-reactive protein level/erythrocyte se

138 of resolution [logMAR]) were recorded during tocilizumab therapy at months 1, 3, 6, and 12.

139 Specific targeting of IL-6 using tocilizumab therapy in patients with rheumatoid arthriti

140 Reinitiation of tocilizumab therapy led to good uveitis control and ME r

141 Prolonged tocilizumab therapy may be safe and effective from early

142 rquartile range, 3.0-5.0) in the year before tocilizumab therapy to 0.4 (interquartile range, 0.0-0.8

143 Mean follow-up with tocilizumab therapy was 15.2 months (range, 12-18 months

144 Tocilizumab therapy was withdrawn in 2 patients because

145 Before tocilizumab therapy, conventional immunosuppressive ther

146 Tocilizumab treatment led to dosage-related decreases in

147 During tocilizumab treatment, the median annualized relapse rat

148 One patient died in relation to tocilizumab treatment.

149 evels (P = .02) dropped significantly during tocilizumab treatment.

150 Three patients remained relapse free during tocilizumab treatment.

151 methotrexate, 1.14, 1.01-1.29, p=0.0356 for tocilizumab vs methotrexate, and p=0.59 for tocilizumab

152 ate vs methotrexate, and 1.86, 1.48-2.32 for tocilizumab vs methotrexate, p<0.0001 for both compariso

153 The safety profile of tocilizumab was consistent with the profiles in previous

154 evere; cytokine blockade with etanercept and tocilizumab was effective in reversing the syndrome and

155 In this study, tocilizumab was effective in the treatment of refractory

156 Tocilizumab was efficacious in severe, persistent system

157 Tocilizumab was given at 8 mg/kg intravenously every 4 w

158 Tocilizumab was mostly well tolerated, with a safety pro

159 Tocilizumab was not associated with a significant reduct

160 d and stopped, then tocilizumab (and placebo-tocilizumab) was also tapered and stopped.

161 occurred in 56% of the patients treated with tocilizumab weekly and in 53% of those treated with toci

162 % of the patients in the group that received tocilizumab weekly, 14% of those in the group that recei

163 r (infliximab), and interleukin-6 inhibitor (tocilizumab) were either negative (abatacept) or were as

164 ukin-6 receptor-blocking monoclonal antibody tocilizumab with or without methotrexate (a conventional

165 stained remission by immediate initiation of tocilizumab with or without methotrexate are more effect

166 In both patients, ME relapsed 3 months after tocilizumab withdrawal.

167 s to test whether an IL-6 receptor antibody, tocilizumab, would improve residual positive and negativ